Narges Ghandi; Shaghayegh Tavassoli; Maryam Ghiasi; Vahideh Lajevardi; Robabeh Abedini; Hamid-Reza Tohidinik; Maryam Daneshpazhooh
Volume 19, Issue 2 , 2016, , Pages 35-39
Ghandi Narges; Tavassoli Shaghayegh; Ghiasi Maryam; Lajevardi Vahideh; Abedini Robabeh; Tohidinik Hamid-Reza; Daneshpazhooh Maryam
Volume 19, Issue 75 , 2016, , Pages 35-13
Abstract
Background: Prolactin (PRL) appears to play a role in the pathogenesis of autoimmune diseases. Limited evidence showed an association between serum PRL levels and the activity of pemphigus vulgaris (PV). This study intends to determine PRL level changes in pemphigus patients during therapy and its correlation ...
Read More
Background: Prolactin (PRL) appears to play a role in the pathogenesis of autoimmune diseases. Limited evidence showed an association between serum PRL levels and the activity of pemphigus vulgaris (PV). This study intends to determine PRL level changes in pemphigus patients during therapy and its correlation with disease type and severity. Methods: In this cohort study, we measured serum PRL levels by enzyme-linked immunosorbent assay (ELISA) in newly diagnosed PV patients at three time points: before therapy initiation and after two and four months. Concomitantly, we estimated disease severity by the Pemphigus Disease Area Index (PDAI). Results: We examined 42 new cases of PV. Among 32 cases who completed the study, mean serum PRL levels at the three time points were 15.9±14.1 ng/mL (before treatment), 16.7±9.8 ng/ mL (2 months after initiation of treatment), and 15.2±9.2 ng/mL (4 months after initiation of treatment). Mean PDAI values were 19.3±12.8 (before treatment), 3.7±6.2 (2 months after initiation of treatment), and 0.6±1.5 (4 months after initiation of treatment). Although the disease activity decreased significantly (P
Wiwanitkit Viroj
Volume 19, Issue 2 , 2016, , Pages 65-65
Abstract
The recent report, “Serum prolactin level in psoriasis”, is very interesting 1. Ghiasi et al. concluded that “it seems that while intracutaneous prolactin may contribute to the pathogenesis of psoriasis, the probable role of pituitary-produced circulating prolactin in the disease process ...
Read More
The recent report, “Serum prolactin level in psoriasis”, is very interesting 1. Ghiasi et al. concluded that “it seems that while intracutaneous prolactin may contribute to the pathogenesis of psoriasis, the probable role of pituitary-produced circulating prolactin in the disease process needs further investigation .” There are some concerns on this report. First, although Ghiasi et al. have studied serum prolactin, they based their conclusion on intracutaneous prolactin. The serum prolactin is not the same as intracutaneous prolactin. The serum prolactin can be affected by several physiological and pathological factors. In fertile females, variations of baseline serum prolactin can be expected. Indeed, for psoriasis, there are previous reports on prolactin with controversial results. The difference in baseline pathophysiological conditions of psoriatic patients can be a good explanation for the different findings on prolactin levels in patients.
Ghiasi Maryam; Hallaji Zahra; Narimani Shaban Ali
Volume 18, Issue 1 , 2015, , Pages 6-9
Abstract
Background: Psoriasis is a chronic immune-mediated skin diseasewith a genetic predisposition. Prolactin may contribute to psoriasispathogenesis. However, there has been a debate over the serumlevel of prolactin in psoriatic patients. The aim of this study was todescribe the role of serum prolactin in ...
Read More
Background: Psoriasis is a chronic immune-mediated skin diseasewith a genetic predisposition. Prolactin may contribute to psoriasispathogenesis. However, there has been a debate over the serumlevel of prolactin in psoriatic patients. The aim of this study was todescribe the role of serum prolactin in the pathogenesis of psoriasisMethod: The serum prolactin level was measured in 45 patientswith psoriasis and in 45 sex- and age-matched healthy individualsusing radioimmunoassay.Result: The mean serum prolactin concentration was not differentbetween psoriatic patients and healthy controls (320 ± 179.38 vs.318.18 ± 191.78 mIU/L, respectively P = 0.95). There was no sexandage-related differences in serum prolactin between the twostudy groups. Hyperprolactinemia (serum prolactin >324 mIU/Lin men, and >496 mIU/L for women) was observed in 11 patientswith psoriasis and 12 healthy subjects, which showed no significantdifference between the two groups (P = 0.81). The serum prolactinwas not significantly correlated with the duration of the disease(r = -0.18, P = 0.24) or the PASI score (r = 0.10, P = 0.50).Conclusion: The possible role of pituitary-produced circulatingprolactin in the disease process needs further investigations.
Azizzadeh Maryam; Malek Mojtaba; Amiri Mehdi; Ghorbani Raheb
Volume 12, Issue 3 , 2009, , Pages 79-81
Abstract
Background: Psoriasis vulgaris is a common chronic and inflammatory disease of skin that its etiology is not completely known. However, it seems that genetic and environmental factors play a role in this disease. In vitro studies show that prolactin as a neurohormone has an etiologic effect on psoriasis. ...
Read More
Background: Psoriasis vulgaris is a common chronic and inflammatory disease of skin that its etiology is not completely known. However, it seems that genetic and environmental factors play a role in this disease. In vitro studies show that prolactin as a neurohormone has an etiologic effect on psoriasis. This study aimed to compare serum prolactin levels in psoriatic patients with control group. Method: Prolactin level in serum was measured with ELISA method in 30 patients with psoriasis vulgaris and in 30 healthy persons as control group, which they had been matched with a view to age and sex. Result: Mean serum prolactin level in psoriatic patients was not significantly higher than control group. However, there was statistically significant relation between severity of disease and serum prolactin levels (r= 0.521, p=0.003). Conclusion: Positive relation between severity of psoriasis vulgaris and serum prolactin levels may suggest that prolactin is an index that shows severity of disease.
M Barzegari; Sh Shams Davachi; A Kianfar
Volume 7, Issue 4 , 2004, , Pages 261-263
Abstract
Background: Prolactin, a neurohormone, can act as a stimulator of immunity in a number of autoimmune diseases and its high levels have been shown in these diseases. Objective: This study was designed to discover the possible role of prolactin in autoimmune blistering skin diseases. The main goal was ...
Read More
Background: Prolactin, a neurohormone, can act as a stimulator of immunity in a number of autoimmune diseases and its high levels have been shown in these diseases. Objective: This study was designed to discover the possible role of prolactin in autoimmune blistering skin diseases. The main goal was to compare the serum prolactin levels and the frequency of hyperprolactinemia in autoimmune skin patients with a control group. Patients and Methods: Serum prolactin levels were measured in 44 patients with autoimmune blistering skin diseases and 44 age and sex matched normal persons. Results: The mean serum prolactin level was higher in the patients group than the control group (13.7 ng/ml vs. 8.4 ng/ml). Seven of 44 patients (16%) had hyperprolactinemia, which was significantly higher than control group (P=0.006). Conclusion: According to this study a higher frequency of hyperprolactinemia was observed in patients suffering from autoimmune blistering diseases in comparison with a control group.